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Abstract 23 
Introduction. Ceftazidime/avibactam combines an established oxyimino-cephalosporin with 24 
the first diazabicyclooctane -lactamase inhibitor to enter clinical use.  We reviewed activity 25 
against Gram-negative isolates, predominantly from the UK, referred for resistance 26 
investigation in the first year of routine testing, beginning July 2015.  Methods.  Isolates were 27 
as received from referring laboratories; there is a bias to submit those with suspected 28 
carbapenem resistance.  Identification was by MALDI-ToF mass spectroscopy, and 29 
susceptibility testing by BSAC agar dilution. Carbapenemase genes were sought by PCR; 30 
other resistance mechanisms were inferred using genetic data and interpretive reading. 31 
Results. Susceptibility rates to ceftazidime/avibactam exceeded 95% for: (i) 32 
Enterobacteriaceae with KPC, GES or other Class A carbapenemases, (ii) 33 
Enterobacteriaceae with OXA-48-like enzymes and (iii) for ESBL or AmpC producers, even 34 
when these had impermeability-mediated ertapenem resistance.  Almost all isolates with 35 
metallo-carbapenemases were resistant.  Potentiation of ceftazidime by avibactam was seen 36 
for 87% of ceftazidime-resistant Enterobacteriaceae with ‘unassigned’ ceftazidime resistance 37 
mechanisms, including two widely referred groups of Klebsiella pneumoniae where no synergy 38 
was seen between cephalosporins and established -lactamase inhibitors. Potentiation here 39 
may be a diazabicyclooctane/cephalosporin enhancer effect.  Activity was seen against 40 
Pseudomonas aeruginosa with derepressed AmpC, but not for those with efflux-mediated 41 
resistance. Conclusions. Of available -lactams or inhibitor combinations, 42 
ceftazidime/avibactam has the widest activity spectrum against problem Enterobacteriaceae, 43 
covering all major types except metallo-carbapenemase producers; against P. aeruginosa it 44 
has a slightly narrower spectrum than ceftolozane/tazobactam, which also covers efflux-type 45 
resistance.  46 
 47 
48 
Introduction 49 
Ceftazidime/avibactam is the first -lactam/diazabicyclooctane -lactamase inhibitor 50 
combination to enter clinical use.1  Avibactam inhibits most ceftazidime-hydrolysing Class A 51 
and C -lactamases, including KPC carbapenemases as well as ESBLs and AmpC 52 
enzymes;2,3 ceftazidime is anyway stable to OXA-48-like carbapenemases4 and has good 53 
antipseudomonal activity. Consequently, the combination has the potential for wide activity 54 
against Enterobacteriaceae with these problem -lactamases and against Pseudomonas 55 
aeruginosa with derepressed AmpC.5,6  -Lactamases that evade inhibition by avibactam 56 
include metallo-carbapenemases and the OXA carbapenemases of Acinetobacter spp.2,3 57 
PHE’s Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) 58 
Reference Unit added ceftazidime/avibactam to its antibiotic panel, tested against all referred 59 
Gram-negative submissions, in July 2015. We review here our experience over the 60 
subsequent 12 months. 61 
 62 
Materials and methods 63 
Isolates 64 
Bacteria were as referred: around 90% were from English diagnostic laboratories, 9% from 65 
other parts of the UK and 1% from overseas, principally the Republic of Ireland.  Most were 66 
submitted owing to unusual resistance and there was a strong current bias towards referral of 67 
isolates suspected of carbapenem resistance, though a few were sent because they were 68 
unusually susceptible, were resistant to non--lactam agents or because the sender had 69 
obtained discrepant results between different test methods.  We excluded isolates tested or 70 
re-tested for internal and external quality assurance and repeat/multiple tests on the same 71 
isolate from the same submission.  72 
  Data were reviewed for one year starting from July 2015, when we began to test 73 
ceftazidime/avibactam routinely; the drug was not licensed or in significant use during this 74 
period.  Numbers of isolates are slightly lower than in a similar analysis for 75 
ceftolozane/tazobactam7 owing to a test failure with ceftazidime/avibactam in one week. 76 
 77 
Identification and resistance investigation 78 
Bacteria were identified by MALDI-ToF mass spectroscopy (Bruker Daltonics, Bremen, 79 
Germany) and MICs determined by BSAC agar dilution.8  Asides from ceftazidime/avibactam 80 
4 mg/L, we tested clinically-used lactams alone or in combination with fixed concentrations 81 
of inhibitors as follows: ampicillin, amoxicillin/clavulanate 2 mg/L, aztreonam, carbenicillin, 82 
cefepime, cefotaxime, cefoxitin, ceftazidime, ceftolozane/tazobactam 4 mg/L, ertapenem, 83 
imipenem, meropenem, piperacillin/tazobactam 4 mg/L and temocillin. To help predict 84 
lactamase types, we additionally tested cefotaxime/clavulanate 2 mg/L, 85 
cefotaxime/cloxacillin 100 mg/L, ceftazidime/clavulanate 2 mg/L, cefepime/clavulanate 2 mg/L 86 
and imipenem/EDTA 320 mg/L.   87 
 Genes for KPC, VIM, NDM and OXA-48-like carbapenemases were sought by multiplex 88 
PCR9 in all Enterobacteriaceae submitted owing to suspected carbapenem resistance and in 89 
those submitted for other reasons, but found to have phenotypes suggesting carbapenemase 90 
production. Enterobacteriaceae found negative for these commonest carbapenemases, but 91 
with phenotypes suggesting carbapenemase production were examined with further multiplex 92 
PCRs seeking (i) blaIMP, blaSPM, blaGIM, blaSIM10 or (ii) blaFRI, blaGES, blaIMI, and blaSME.11 The first 93 
of these multiplexes was also used for P. aeruginosa isolates showing imipenem/EDTA 94 
synergy together with broad resistance to penicillins and cephalosporins. 95 
 The genomes of carbapenemase producers with unusual behaviour were sequenced, 96 
using Illumina methodology, as were representatives of two unusual phenotypes of Klebsiella 97 
pneumoniae (see Results).  Sequenced genomes were searched against our locally-curated 98 
database of antimicrobial resistance determinants using AMRHAI’s GeneFinder algorithm.12 99 
Searches for new β–lactamases were performed on assembled-contigs translated in the six 100 
possible reading frames using PSI-BLAST (position-specific iterated BLAST) and the HMM-101 
based (Hidden Markov Models) method in the HMMer software suite (v3.1).13 HMMER 102 
searches were performed at increasingly stringent thresholds using the β-lactamase-related 103 
pfam domains obtained from public databases.14 Clover leaf/Hodge tests were performed on 104 
selected organisms, seeking to detect hydrolysis of carbapenems (using 10 g ertapenem, 105 
imipenem and meropenem discs) or oxyimino-cephalosporins (using 30 g cefepime, 106 
cefotaxime and ceftazidime discs); Escherichia coli ATCC 25922 was the indicator organism 107 
throughout. 108 
 109 
Categorisation of isolates by resistance mechanisms  110 
Molecular detection of a carbapenemase gene was considered definitive. Mechanisms in 111 
isolates lacking carbapenemase genes were assigned based on interpretive reading15,16 of 112 
phenotypes, using an in-house algorithm. Two levels of match were allowed: 'Hard', where the 113 
phenotype was a perfect match and 'Soft', where the phenotype was less perfect, but the 114 
mechanism remained the most likely.7 Some isolates did not match any well-recognised 115 
phenotype considered and were left as ‘unassigned’.    116 
 117 
Results 118 
Distribution of resistance mechanisms by species group 119 
Among the 3144 referred Enterobacteriaceae isolates tested, 907 (28.8%) had 120 
carbapenemase genes, predominantly blaOXA-48-like, blaNDM or blaKPC, while 898 (28.6%) 121 
had AmpC phenotypes and lacked carbapenemase genes and 655 (20.8%) had 122 
ESBL phenotypes, again lacking carbapenemase genes (Table 1).  Fully 80% of the 123 
AmpC producers and 58.5% of the ESBL producers were non susceptible to ertapenem at 124 
EUCAST’s 0.5 mg/L breakpoint, whilst 13.7% and 6.3%, respectively were non-susceptible to 125 
meropenem at 2 mg/L.  These proportions considerably exceed those for AmpC and ESBL 126 
producers in general 17,18 and we infer that many of these organisms also had reduced 127 
permeability, which is a general correlate of ertapenem resistance among AmpC and ESBL 128 
producers.19  129 
 Smaller numbers of isolates had phenotypes suggesting: (i) co-production of AmpC 130 
and ESBL enzymes, with clavulanate potentiating cefepime, but not ceftazidime or cefotaxime 131 
(n=71, 2.3%); (ii) hyper-production of K1 enzyme (in K. oxytoca isolates, n=8, 0.25%), or (iii) 132 
reduced permeability alone (n=85, 2.7%).  One hundred and forty-one referrals (4.5%) had 133 
wild-type phenotypes with respect of lactams; these mostly had been submitted owing to 134 
resistance to other antibiotic classes.  Finally, 379 (12.1%) had resistance patterns that were 135 
not predictive of any particular mechanisms: these varied widely in their phenotypes of 136 
resistance to different -lactams, but universally lacked cephalosporin/clavulanate or 137 
cefotaxime/cloxacillin synergy (see below). 138 
 139 
Isolates with carbapenemases 140 
Modal ceftazidime MICs for isolates with KPC enzymes fell from 16 mg/L to 0.5 mg/L when 141 
avibactam was added, and those for isolates with GES enzymes from 256 to 1 mg/L (Table 142 
2). Only two isolates with KPC carbapenemases – an Enterobacter sp. and a K. pneumoniae, 143 
were resistant to ceftazidime/avibactam at its 8+4 mg/L breakpoint.  Resistance was stable in 144 
the K. pneumoniae isolate, where genome sequencing revealed classical blaKPC-2, without the 145 
mutations associated with ceftazidime/avibactam resistance.20,21 Resistance in the 146 
Enterobacter was lost on subculture, precluding investigation.  Eleven isolates had other class 147 
A carbapenemases – specifically IMI, SME and FRI types. These were resistant to ertapenem 148 
(MICs 4->16 mg/L) and non-susceptible to either or both of imipenem (MICs 8->128 mg/L) 149 
and meropenem (MICs 4->32 mg/L, except one IMI isolate, 0.12 mg/L); all except one were 150 
susceptible or borderline resistant to unprotected ceftazidime (MICs 0.25-2 mg/L), with only 151 
limited avibactam synergy, e.g. for the E. cloacae strain with FRI-2,22 where the ceftazidime 152 
fell from 0.5 to 0.25 mg/L.       153 
 The MIC distribution of ceftazidime for OXA-48 Enterobacteriaceae was bimodal, with 154 
peaks at 0.5 and >256 mg/L; 34.8% of isolates inhibited by unprotected ceftazidime at 155 
EUCAST’s 1 mg/L susceptible breakpoint and 45.0% at the 4 mg/L resistance breakpoint. 156 
With avibactam added, this distribution became unimodal, with a peak at 0.25 mg/L and 94% 157 
of MICs between 0.12 and 2 mg/L. Potentiation was <4-fold for isolates with ceftazidime MICs 158 
<1 mg/L, but 128- to 1024-fold for those with high-level ceftazidime resistance. Five OXA-48 159 
isolates (two K. pneumoniae from separate hospitals and single K. oxytoca, E. coli and C. 160 
freundii) tested as resistant to ceftazidime/avibactam, with MICs >32+4 mg/L but this was not 161 
confirmed on retesting and was not pursued further. 162 
 Isolates with metallo-carbapenemases consistently were resistant to ceftazidime and 163 
remained so with avibactam added. The few exceptions to this generalisation were E. coli that 164 
were inhibited by avibactam alone at 4 mg/L (Table 2). 165 
 166 
Isolates with ESBLs, AmpC and other mechanisms  167 
As already stressed, referred AmpC and ESBL producers are biased towards those with 168 
reduced susceptibility to carbapenems. To accommodate this bias, ceftazidime/avibactam 169 
MICs for these isolates are shown, ESBL producers (Table 3) and AmpC 170 
hyperproducers(Table 4), in relation to those of ertapenem, as a proxy for impermeability. The 171 
AmpC isolates mostly were Enterobacter spp., where ertapenem MICs of 1-2 mg/L are typical 172 
for AmpC-derepressed strains; the ESBL producers were mostly E. coli and K. pneumoniae 173 
(Table 1).  174 
 Among the ESBL producers, 96.2% were non-susceptible to ceftazidime 1 mg/L and 175 
77.8% were highly resistant, with MICs 32->256 mg/L; corresponding proportions among the 176 
AmpC producers were 93.9% and 74.1%, respectively. With avibactam added, the ceftazidime 177 
MICs were reduced to <8+4 mg/L (i.e. susceptible) for 99.7% of ESBL producers and 98.3% 178 
with AmpC. The MICs of ceftazidime/avibactam for ESBL producers trended upwards as the 179 
ertapenem MIC increased from 0.12 to 1 mg/L, but with little further rise for highly-ertapenem 180 
resistant isolates. This behaviour contrasted to ceftazidime/clavulanate (not shown) and 181 
ceftolozane/tazobactam,7 where MICs rose progressively with the ertapenem MIC.  MICs of 182 
ceftazidime/avibactam for AmpC producers did rise in parallel with ertapenem MICs but the 183 
combination remained active against 109/115 isolates with ertapenem MICs >16 mg/L. Fifteen 184 
of the 898 AmpC producers were resistant to ceftazidime/avibactam 8+4 mg/L; four of these 185 
were Hafnia alvei (versus 12 H. alvei among the whole 898) and eight were ‘Soft 186 
matches’(versus 65 Soft matches among the 898) implying a greater risk that they were mis-187 
categorisations or had secondary mechanisms. Two Soft-matched ESBL K. pneumoniae were 188 
resistant to ceftazidime/avibactam; both were among the most–highly-ertapenem resistant 189 
(MICs >16 mg/L) and probably represent extreme examples of impermeability. 190 
 Among isolates with both AmpC and ESBL activity, 69/71 (97.2%) were susceptible to 191 
ceftazidime/avibactam 8+4 mg/L whereas MICs of unprotected ceftazidime were >128 mg/L 192 
in 66/71 cases..  Only eight K1 -lactamase-hyperproducing K. oxytoca were included: these 193 
had characteristic resistance to piperacillin/tazobactam and aztreonam, but with MICs around 194 
EUCAST breakpoints for oxyimino-cephalosporins and 4- to 32-fold cefepime/ and 195 
cefotaxime/clavulanate synergy.15,16 MICs of unprotected ceftazidime were from 0.25-2 mg/L, 196 
falling to 0.12-1 mg/L with avibactam added.   Last, among characterised groups, 85 isolates 197 
were inferred solely to have reduced permeability, with cefoxitin MICs >32 mg/L and 198 
ertapenem MICs (>0.5 mg/L in 64/85 cases). Oxyimino-cephalosporin MICs remained around 199 
breakpoints (0.5-4 mg/L) with (i) no differential between cefepime and other oxyimino-agents, 200 
and (ii) no cephalosporin synergy with cloxacillin or clavulanate. MICs of unprotected 201 
ceftazidime were 0.5-4 mg/L and remained in this range with ceftazidime/avibactam in 71/85 202 
cases, falling slightly for the remaining 14. 203 
  204 
Unassigned isolates 205 
The 379 organisms with unassigned mechanisms were dominated by K. pneumoniae (n=203) 206 
and E. coli (n=124) (Table 1). The major common feature, along with some degree of 207 
cephalosporin resistance, was the absence of synergy between cephalosporins and 208 
clavulanate or cloxacillin, and between imipenem and EDTA. The lack of 209 
ceftazidime/clavulanate synergy is illustrated in fig 1a. Prior to adding ceftazidime/avibactam 210 
to the test panel, we believed that these isolates mostly had -lactamase-independent,  modes 211 
of resistance but subsequently were surprised by the large proportion with potentiation was 212 
seen.  Thus, among all 379 isolates, 199 were resistant to ceftazidime 8 mg/L and 195 to 213 
ceftazidime/clavulanate 8+2 mg/L but only 26 to ceftazidime/avibactam 8+4 mg/L (fig 1b).   214 
  Two regularly-seen K. pneumoniae phenotypes (‘Type I’ and ‘Type II’) accounted for 215 
many of these isolates, and MIC data are illustrated in Table 5. Type I isolates were resistant 216 
to cefepime and ceftazidime, with MICs 8-64 mg/L, but remained borderline susceptible to 217 
cefotaxime, with MICs 1-4 mg/L. Type II isolates were resistant to all  three oxyimino-218 
cephalosporins, with MICs 32->256 mg/L.  Both types were resistant to cefoxitin, 219 
piperacillin/tazobactam, and amoxicillin/clavulanate.  Temocillin MICs were raised above the 220 
4-8 mg/L values typical for K. pneumoniae, but mostly remained <64 mg/L. Carbapenem MICs 221 
were raised, with almost all non-susceptible to ertapenem at EUCAST's 0.5 mg/L breakpoint; 222 
many, particularly among Type II isolates, were highly resistant, with MICs >16 mg/L.  Both 223 
types have been referred from multiple hospitals over the past 3-4 years and are non-clonal, 224 
based on Variable Number Tandem Repeat typing.22 They varied in fluoroquinolone and 225 
aminoglycoside susceptibility.  Crucially, while cephalosporin MICs were not reduced by 226 
clavulanate or cloxacillin, those of ceftazidime were reduced  by avibactam, mostly falling to 227 
1-4 mg/L.  228 
Whole genome sequencing of 10 Type I representatives, mostly pre-dating the present 229 
series, confirmed clonal diversity and found seven to have only the SHV-1 -lactamase typical 230 
of K. pneumoniae, without mutations to the coding or promoter sequences; single 231 
representatives had SHV-27 (an ESBL), SHV-36 (unknown spectrum) or SHV-1 plus TEM-10 232 
(an ESBL). Increased read depth, relative to gyrA and parC, suggested that blaSHV was 233 
amplified in most cases whilst ompK35 was inactivated by an identical frame shift mutation in 234 
all isolates and ompK36 was inactivated in most by various mutations or insertions. The genes 235 
encoding the essential PBPs (1, 2 and 3) were conserved, without mutations. Sequencing of 236 
four Type II isolates variously revealed CTX-M-15 plus OXA-1, CMY-42 plus OXA-1, CTX-M-237 
15, OXA-1 plus SHV-53 and CTX-M-33, OXA-1, SHV-11 and TEM-1.  238 
None of the genetic changes seen for Type I isolates adequately explains their phenotypes 239 
(see Discussion).  Further bioinformatic analysis failed to find motifs suggesting additional 240 
lactamase genes, and clover leaf (Hodge) tests were negative for both carbapenems and 241 
oxyimino-cephalosporins.   242 
 243 
Pseudomonas aeruginosa 244 
Data were obtained for 1384 P. aeruginosa. Analysis must be cautious because, unlike for 245 
Enterobacteriaceae, we used ceftazidime/avibactam in categorising these isolates,7 246 
distinguishing those with derepressed AmpC (carbenicillin MIC <128 mg/L, cefotaxime MIC > 247 
carbenicillin MIC and ceftazidime MIC > 4x ceftazidime/avibactam MIC) from those with up-248 
regulated efflux (carbenicillin, piperacillin/tazobactam and ceftazidime MICs raised in 249 
approximate proportion, without ceftazidime/avibactam potentiation).   250 
Among 147 putative AmpC-derepressed P. aeruginosa, 94.6% were susceptible to 251 
ceftazidime/avibactam 8+4 mg/L versus 21.0% to ceftazidime 8 mg/L and 96.6% to 252 
ceftolozane/tazobactam 4+4 mg/L.  Among 388 with moderately raised efflux (carbenicillin 253 
MICs 256-512 mg/L), 86.1% were susceptible to ceftazidime/avibactam, 65.7% to ceftazidime 254 
and 99.7% to ceftolozane/tazobactam.  Among 149 with highly raised efflux (carbenicillin MICs 255 
>512 mg/L), 41.6% were susceptible to ceftazidime/avibactam, 27.5% to ceftazidime and 256 
95.3% to ceftolozane/tazobactam. The gain versus AmpC-derepressed isolates doubtless 257 
reflects -lactamase inhibition of; that versus ‘efflux isolates’ was largely a thresholding effect, 258 
with the ceftazidime MIC reduced from 16 to 8 mg/L thus crossing the breakpoint but remaining 259 
within one doubling dilution of the ceftazidime value.  Four hundred and ten P. aeruginosa 260 
isolates were non-susceptible to all of carbenicillin, piperacillin/tazobactam, ceftazidime, 261 
imipenem and meropenem at EUCAST breakpoints.  Of these, 28.7% were susceptible to 262 
ceftazidime/avibactam 8+4 mg/L and 52.6% to ceftolozane/tazobactam 4+4 mg/L, rising to 263 
43.3% and 81.6%, respectively, if isolates with metallo-carbapenemases (n = 118, mostly VIM 264 
types), ESBLs (n = 31 mostly VEB ) or GES enzymes (n = 4) were excluded.   265 
 266 
Discussion 267 
These data are for ‘problem’ isolates sent to PHE’s reference laboratory, and therefore with a 268 
heavy bias to resistance.  They show ceftazidime/avibactam broadly active against: (i) 269 
Enterobacteriaceae with KPC, GES and other class A carbapenemases, (ii) 270 
Enterobacteriaceae with OXA-48-like enzymes, irrespective of susceptibility to ceftazidime 271 
alone, and (iii) Enterobacteriaceae with ESBLs or AmpC enzymes, irrespective of the 272 
impermeability traits that confer resistance to ertapenem.  Lastly, ceftazidime/avibactam 8+4 273 
mg/L remained active against 87% (fig. 1b) of the 199 Enterobacteriaceae with unassigned 274 
mechanisms, but which were resistant to ceftazidime alone at 8 mg/L, including members of 275 
the widely encountered Type I and II phenotypes of K. pneumoniae illustrated in Table 5.   276 
 Activity against KPC-, ESBL- and AmpC- producers is in keeping with the known ability 277 
of avibactam to inhibit these enzymes.2,3  Ceftazidime itself remains active against a sizeable 278 
minority of Enterobacteriaceae with OXA-48-like enzymes, whereas others are highly 279 
resistant, as illustrated by the bi-modal MIC distribution in Table 2. The explanation is that 280 
OXA-48-like enzymes do not, themselves,4 attack ceftazidime, but that many producers also 281 
have further mechanisms - most often ESBLs23 - that confer resistance.  Avibactam gave weak 282 
potentiation of ceftazidime against ceftazidime-susceptible isolates with OXA-48-like 283 
enzymes, but strongly potentiated ceftazidime against those with high-level resistance, 284 
presumably via inhibition of these secondary -lactamases. 285 
 The only major gaps in ceftazidime/avibactam’s spectrum, as is well recognised,2,3  286 
were metallo-carbapenemase producers. These accounted for a little over one-third of 287 
carbapenemase-producing Enterobacteriaceae referred to AMRHAI (302/873 = 34.6% in the 288 
period reviewed).  Their actual proportion may be lower since: (i) isolates with KPC 289 
carbapenemases are concentrated in a few hospitals in Northwest England, which no longer 290 
refer all producers, and (ii) isolates with metallo-carbapenemases, particularly NDM, are highly 291 
resistant and unlikely to be missed, whereas many with OXA-48-like enzymes have marginal 292 
carbapenem resistance, likely leading to under-detection. Proportions of non-metallo- versus 293 
metallo-carbapenemases vary globally, with KPC types predominating in the Americas, Italy, 294 
Greece and China; OXA-48 in Turkey, Romania and Spain, and NDM in South Asia; strains 295 
with both OXA-48 and NDM appear prevalent in the Middle East.24,25  296 
 A few isolates with KPC and OXA-48 enzymes were resistant to ceftazidime/avibactam 297 
on primary testing, but resistance was only confirmed for one K. pneumoniae with a KPC 298 
carbapenemase. It is impossible to ascertain whether initial results for the others were in error 299 
or whether unstable resistance had been lost. Sequencing revealed that the stably-resistant 300 
K. pneumoniae isolate produced KPC-2 carbapenemase and its behaviour possibly reflected 301 
the activity of this enzyme together with impermeability. It lacked the blaKPC mutations 302 
associated with emerging ceftazidime/avibactam resistance during therapy, and found also in 303 
mutants generated in vitro; these cluster around the -loop and increase affinity for 304 
ceftazidime, protecting against binding of avibactam.20,21,26  Emerging resistance to 305 
ceftazidime/avibactam in an isolate with an OXA-48 enzyme was associated with Pro170Ser 306 
and Thr264Ile substitutions to a co-produced CTX-M-14 ESBL, without changes to OXA-48 307 
itself.27   308 
 Retained activity against isolates with combinations of ESBL or AmpC and 309 
impermeability was striking.  Although such strains rarely cause outbreaks and often are 310 
unstable, they are not infrequent and can be selected during carbapenem therapy, 311 
complicating treatment .28,29   312 
 The broad activity of ceftazidime/avibactam against ceftazidime-resistant isolates with 313 
unassigned mechanisms is intriguing, especially as these were almost all resistant to 314 
ceftazidime/clavulanate (fig. 1). The obvious explanation is that these isolates have 315 
unsuspected lactamases, inhibited by avibactam, but not by clavulanate, cloxacillin or 316 
tazobactam.  However, for the two largest groups, i.e. the Type I and II K. pneumoniae in 317 
Table 5 – we have been unable to find any such enzyme: the Type I isolates largely have an 318 
increased copy number classical blaSHV-1, which is chromosomal and ubiquitous in K. 319 
pneumoniae,30 along with inactivation of ompK35 and ompK36, whilst the Type II unknowns 320 
had various ESBL or AmpC enzymes. Further analysis has concentrated on the Type I isolates 321 
as the simpler case.  A quarter century ago, Petit et al.31 cautiously associated increased 322 
expression of SHV-1 enzyme with resistance to ceftazidime but not cefotaxime in K. 323 
pneumoniae, as in our Type I isolates. However, (i) their strains, unlike ours, had 324 
ceftazidime/clavulanate synergy, as would be expected, and (ii) they did not seek non--325 
lactamase-mediated mechanisms.  It may be that the porin mutations in our isolates excluded 326 
clavulanate more effectively that avibactam, reconciling this discrepancy. But, if so, the 327 
distinction was remarkably clear cut, whereas significant cephalosporin/clavulanate synergy 328 
typically is retained for impermeable, ertapenem-resistant, ESBL producers of the type 329 
detailed in the bottom rows of Table 3 (see also ref. 19).   An alternative hypothesis, 330 
speculative but plausible, is that these organisms have some perturbation (in the broadest 331 
sense) of cell wall synthesis that simultaneously confers (a) reduced susceptibility to multiple 332 
-lactams and (b) vulnerability ceftazidime/avibactam synergy by a mechanism other than -333 
lactamase inhibition.  Potentiation of cephalosporins independently of -lactamase inhibition 334 
is a common feature of other DBOs, notably nacubactam (RG6080/OP0595) or zidebactam 335 
and seems to depend on the DBO interacting with PBP2 whilst the partner -lactam attacks 336 
PBP3.32  The absence of PBP gene changes in K. pneumoniae with the Type I and II 337 
phenotypes does not refute these speculations, for it is established that the consequence of 338 
DBO- and mecillinam- mediated inhibition of PBP2 are modulated by mutations to genes 339 
involved in the stringent response rather than directly in peptidoglycan biogenesis.  The threat 340 
posed by these phenotypes is debatable: on the one hand they are widely scattered and 341 
regularly referred, moreover the Type II isolates are very broadly resistant to -lactams other 342 
than ceftazidime/avibactam; on the other hand we have not seen outbreaks, and susceptibility 343 
rates to non--lactams are high, particularly for Type I isolates, meaning that treatment options 344 
remain (Table 5). 345 
 We have only included a limited analysis for P. aeruginosa because we used 346 
ceftazidime/avibactam MICs to help categorise resistance mechanisms.7 Nevertheless the 347 
findings are entirely compatible with the view, inherently plausible and supported by previous 348 
work, that avibactam substantially overcomes AmpC-mediated ceftazidime resistance,6 but 349 
not that due to efflux. Ceftolozane/tazobactam, by contrast, retains activity against >95% of 350 
isolates with either of these mechanisms.7 Neither inhibitor combination overcomes metallo-351 
carbapenemases nor VEB-type ESBL-mediated resistance in the species, but these 352 
mechanisms are uncommon in the UK. 353 
 In summary, these data show that ceftazidime/avibactam has activity against most 354 
problem Enterobacteriaceae groups seen in the UK, as referred to the national reference 355 
laboratory. Its activity extends to two frequently-referred K. pneumoniae phenotypes where 356 
ceftazidime resistance is not obviously lactamase-mediated; these remain under active 357 
investigation. The isolates studied here pre-date clinical use of ceftazidime/avibactam in the 358 
UK and,  as the drug enters use, attention will need to be paid to any emergence of resistance.  359 
Shields and colleagues, in Pittsburgh, saw emerging resistance in 3/31 cases where 360 
ceftazidime/avibactam was used to treat severe infections due to K. pneumoniae ST258 with 361 
KPC carbapenemases.21 These mutations –and similar ones selected by ourselves in vitro- 362 
make KPC enzymes into ‘better’ ceftazidimases,20,26 but also reduce carbapenemase activity. 363 
An interesting possibility is that co-administration of meropenem might block this route to 364 
resistance, counter-selecting against any mutation that degraded carbapenemase activity and 365 
thus ‘forcing’ the KPC enzyme to remain vulnerable to avibactam.   366 
 367 
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Table 1.  Referred isolates, by detected or inferred resistance mechanism 483 
 Carbapenemases Non-carbapenemases Other, uncertain  
 KPC GES 
Other 
class 
Aa  
OXA-
48-like MBLb 
NDM + 
OXA-
48 AmpC ESBL  
ESBL+ 
AmpC K1  
Imperm-
eable  
Wild-
type  
Unas-
signed  
Grand 
Total 
Citrobacter spp. 4   13 12  45 2 1   2 4 83 
E. coli 33 4  127 93 4 116 352 42  35 33 124 963 
Enterobacter spp. 26c 1 7 40 28  633 47 20   45 25 872 
H. alvei       12      0 12 
K. oxytoca 4 15  6 3   3  8 1 2 13 55 
K. pneumoniae 130 3  142 160 28 49 248 8  49 18 203 1038 
M. morganii     2  8     14 0 24 
Providencia spp.     4  1     2 1 8 
Rare fermenters 2 1  1    2    6 2 14 
Serratia spp. 4 1 4 4 1  34 1    19 7 75 
Grand Total 203 25 11 333 303 32 898 655 71 8 85 141 379 3144 
Hard matchd Not applicable; molecular identification of mechanism(s) 833 599 53 8 85 141 N/A  
Soft matchd       65 56 18 0 0 0 N/A  
 484 
a 6 IMI, 4 SME and 1 FRI-2. 485 
b MBL, metallo--lactamases, 242 NDM, 36 VIM, 24 IMP and 1 with both IMP and NDM 486 
c Includes one isolate also with an OXA-48 enzyme as well as a KPC type 487 
d Hard match: phenotype perfectly matches that expected for the mechanism; Soft: phenotype best matches this mechanism, but with minor anomalies 488 
  489 
Table 2.  MICs of ceftazidime and ceftazidime/avibactam for carbapenemase-producing Enterobacteriaceae isolates 490 
  No isolates with indicated MIC, mg/L 
Enzyme 
Ceftazidime  
+/-AVI 
0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256 
Class A                
KPC (202) Alone      
4 20 47 52 39 14 7 11 8 
 +AVI  8 39 78 56 13 6    2*    
GES (25) Alone        2 1  4 4 11 3 
 +AVI 1   1 5 15 3        
IMI (6) Alone   2 2  1  1       
 +AVI  1 1 4           
SME (4) Alone     1 3         
 +AVI    2 2          
FRI-2 (1) Alone    1           
 +AVI   1            
Class D                
OXA-48-like (333) Alone  
6 34 40 36 24 10 26 10 13 28 32 36 38 
 +AVI 9 39 85 83 81 25 5 1   5*    
Class B                
NDM (242) Alone           
1   241 
 +AVI 2   1      2 237*    
VIM (36) Alone          
1 6 11 13 5 
 +AVI       1  7 9 19*    
IMP (24) Alone           
1 1 4 18 
 +AVI          1 23*    
Multiple, no MBL                
KPC+OXA-48-like 
(1) 
Alone          1     
 +AVI     1          
Multiple, inc. MBL                
NDM+OXA-48-like 
(32) 
Alone        
1   1   30 
 +AVI      1  1   30*    
NDM+IMP (1) Alone              1 
 +AVI           1*    
 491 
Abbreviations: AVI, avibactam 4 mg/L; MBL, metallo--lactamase 492 
* MIC > indicated value 493 
 494 
 495 
  496 
Table 3.   MICs of ceftazidime/avibactam in relation to ertapenem for referred ESBL producers 497 
Ertapenem MIC (mg/L) 
No. isolates with indicated ceftazidime/avibactam MIC (mg/L) 
Grand 
Total 
<0.06 0.125 0.25 0.5 1 2 4 8 16 >16  
<0.12 13 50 77 20 3 1     164 
0.25  5 16 24 9 2 1    57 
0.5 3 1 11 19 6 9 2    51 
1 3 4 3 23 28 12 3    76 
2 7 5 4 26 25 13 4    84 
4 3 7 11 12 17 12 1 2   65 
8 2 2 5 26 17 11 1 2   66 
16 2 1 4 16 21 6 2  1  53 
>16    5 23 5 3 2 1  39 
Grand Total 33 75 131 171 149 71 17 6 2  655 
MICs of unprotected ceftazidime   3 6 16 16 36 45 80 429  
 498 
For each ertapenem MIC the three dilutions accounting for most ceftazidime/avibactam MICs are highlighted in bold  499 
  500 
Table 4.   MICs of ceftazidime/avibactam in relation to ertapenem for referred AmpC producers 501 
Ertapenem MIC (mg/L) 
No. isolates with indicated ceftazidime/avibactam MIC (mg/L) 
Grand 
Total 
<0.06 0.125 0.25 0.5 1 2 4 8 16 32 >32  
<=0.12 6 25 25 7 1 2  1 1   68 
0.25 3 2 6 7 8  1     27 
0.5  3 20 26 20 9 3  1  2 84 
1 1  21 45 43 15 3     128 
2 2 6 12 51 97 16 4 1    189 
4 2 1 3 23 62 36 5 1   1 134 
8 1 3 6 16 35 27 5 2 1  1 97 
16 1 2 2 10 14 18 6  1 1  55 
>16   3 18 28 26 22 12 1 2 3 115 
Grand Total 16 42 98 203 308 149 49 17 5 3 7 897a 
MICs of unprotected 
ceftazidime 
 1 5 15 34 48 29 42 59 115 549 
 
 502 
For each ertapenem MIC the three dilutions accounting for most ceftazidime/avibactam MICs are highlighted in bold  503 
a Total is 897 not 898 (see Table 1) owing to one test failure with ertapenem  504 
Table 5.  MICs of ceftazidime/avibactam and comparators against K. pneumoniae Types I and II, with unknown modes of resistance 505 
 No isolates with indicated MIC (mg/L) 
 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256 
Type I               
Ceftazidime        3 8 17 10    
Ceftazidime/clavulanate       1 2 13 14 8*    
Ceftazidime/avibactam   2 2 9 14 5 5 1      
Cefepime        7 19 5 7    
Cefepime/clavulanate      1 3 10 12 9 3*    
Cefotaxime     12 14 12        
Cefotaxime/clavulanate    4 11 17 6        
Cefotaxime/cloxacillin    2 15 15 5  1      
Ceftolozane/tazobactam      8 15 10 5      
Piperacillin/tazobactam          1  37*   
Amoxicillin/clavulanate           1 37*   
Cefoxitin         1 3 12 22*   
Temocillin        3 18 10 7    
Aztreonam (1 nt)     1 9 16 7 16      
Ertapenem    2 2 4 3 3 10 14*     
Meropenem  4 3 4 3 10 6 6 2      
Imipenem  1 3 7 11 8 5 1 2      
Ciprofloxacin  15** 11 9 1  1  1*      
Gentamicin  3** 12 19 2  1        
Amikacin    8** 17 10 1 1  1     
Type II               
Ceftazidime          3 3 14 36 26* 
Ceftazidime/clavulanate         1 14 67*    
Ceftazidime/avibactam    6 21 33 15 7       
Cefepime          3 2 77*   
Cefepime/clavulanate        1 2 6 73*    
Cefotaxime         5     77 
Cefotaxime/clavulanate       3  2     77 
Cefotaxime/cloxacillin       1 2 1 1   1 76 
Ceftolozane/tazobactam      1  1 3 77*     
Piperacillin/tazobactam            82*   
Amoxicillin/clavulanate            82*   
Cefoxitin          2 27 53*   
Temocillin        1 5 34 38 13 1*  
Aztreonam (2  nt)        2 2   76*   
Ertapenem         16 66*     
Meropenem    1 3 12 22 34 8 2     
Imipenem   3 7 28 29 9 2 4      
Ciprofloxacin  6** 3 1 2 4 5 5 56*      
Gentamicin   10 16 4 1   1 1 48*    
Amikacin    4** 12 5 20 23 15 1 1 1*   
               
* MIC > indicated value 506 
** MIC < indicated value 507 
nt, not tested 508 
Because the mechanisms of resistance in these isolates remain unknown, precise definitions are difficult and the inclusion or exclusion of some isolates is 509 
arguable; accordingly total numbers of isolates included should be viewed with caution 510 
511 
Figure legends 512 
 513 
MIC distributions of (a) ceftazidime/clavulanate and (b) ceftazidime/avibactam in relation to those of unprotected ceftazidime for 514 
Enterobacteriaceae (n=379) with unassigned resistance mechanisms 515 
 516 
  517 
Figure 1.   518 
Panel a) 519 
  MIC ceftazidime (mg/L)   
Ceftazidime/ 
clavulanate  
 MIC (mg/L) 
<0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256 
Grand 
Total 
<0.125 3 4            7 
0.25 3 16 10 1          30 
0.5  1 28 10 1         40 
1  1 2 21 9         33 
2    3 21 7 3       34 
4     5 12 5       22 
8     2 4 7 3 2     18 
16       1 13 10 1    25 
32        1 19 8 16   44 
>32         2 12 9 42 61 126 
Grand Total 6 22 40 35 38 23 16 17 33 21 25 42 61 379 
 520 
 521 
  522 
Panel b) 523 
Ceftazidime/ 
avibactam  
MIC (mg/L) 
MIC ceftazidime (mg/L)  
<0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256 
Grand 
Total 
<0.06 2 3 5  3  1  2     16 
0.125 3 11 7 1 3 3 1       29 
0.25 1 8 20 6 4 1  1 2    1 44 
0.5   6 17 12 1 2  3  4 2  47 
1   2 11 11 4 5 8 11 6 14 12  84 
2     4 12 2 6 10 3 3 23 15 78 
4     1 2 4 1 3 5 1 3 14 34 
8       1 1 1 5 1 1 11 21 
16         1 1 1 1 9 13 
32             3 3 
>32          1 1  8 10 
Grand Total 6 22 40 35 38 23 16 17 33 21 25 42 61 379 
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